- Home
- ICLR
ICLR
ICON plc
as 01-21-2025 4:00pm EST
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.2B | IPO Year: | 1998 |
| Target Price: | $284.82 | AVG Volume (30 days): | 910.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.99 | EPS Growth: | 44.49 |
| 52 Week Low/High: | $183.38 - $347.72 | Next Earning Date: | 02-19-2025 |
| Revenue: | $8,306,823,000 | Revenue Growth: | 3.63% |
| Revenue Growth (this year): | 3.99% | Revenue Growth (next year): | 2.19% |
Latest ICON plc News
ICLR Breaking Stock News: Dive into ICLR Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Icon sees FY25 adjusted EPS $13.00-$15.00, consensus $14.93
Business Wire
8 days ago
ICON Issues Financial Guidance for Full Year 2025
Insider Monkey
9 days ago
What Makes ICON Public Limited Company (ICLR) a High-Quality Contender in the CRO Industry?
Insider Monkey
14 days ago
What Makes ICON Public Limited Company (ICLR) a Prospective Investment?
Business Wire
14 days ago
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
TipRanks
15 days ago
Icon price target lowered to $290 from $300 at Citi
MT Newswires
15 days ago
RBC Initiates ICON PLC at Outperform With $263 Price Target
Business Wire
15 days ago
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare ICLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.